|
|
Line 18: |
Line 18: |
| <font color="#FFF"> | | <font color="#FFF"> |
| ▸ '''Newborn Conjunctivitis''' | | ▸ '''Newborn Conjunctivitis''' |
| </font>
| |
| </div>
| |
|
| |
| <div style="border-radius: 0 0 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;">
| |
| <font color="#FFF">
| |
| '''Viral Conjunctivitis'''
| |
| </font> | | </font> |
| </div> | | </div> |
Line 29: |
Line 23: |
| <div class="mw-customtoggle-table15" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | | <div class="mw-customtoggle-table15" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> |
| <font color="#FFF"> | | <font color="#FFF"> |
| ▸ '''Gram-Negative Cocci in Pairs''' | | ▸ '''Viral Conjunctivitis''' |
| </font>
| |
| </div>
| |
| | |
| <div class="mw-customtoggle-table16" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Gram-Negative Coccobacilli'''
| |
| </font>
| |
| </div>
| |
| | |
| <div class="mw-customtoggle-table17" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
| |
| <font color="#FFF">
| |
| ▸ '''Gram-Negative Bacilli'''
| |
| </font> | | </font> |
| </div> | | </div> |
Line 107: |
Line 89: |
| | valign=top | | | | valign=top | |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Cocci in Pairs}} | | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Viral Conjunctivitis (pink eye)}} |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] 4 MU IV q4h'''''<BR> OR <BR> ▸ '''''[[Ampicillin]] 2 g IV q4h'''''<BR> OR <BR> ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''
| |
| |-
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table16" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Coccobacilli}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 1—1.5 g IV q6h'''''<BR> OR <BR> ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''
| |
| |-
| |
| |}
| |
| |}
| |
| {| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table17" style="background: #FFFFFF;"
| |
| | valign=top |
| |
| {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
| |
| ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Gram-Negative Bacilli}}
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen'''''
| |
| |-
| |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 2 g IV q4—6h'''''<BR> OR <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |-
| |
| | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternative Regimen'''''
| |
| |- | | |- |
| | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''<BR> OR <BR> ▸ '''''[[Aztreonam]] 2 g IV q6—8h'''''<BR> OR <BR> ▸ '''''[[Moxifloxacin]] 400 mg IV q24h'''''<BR> OR <BR> ▸ '''''[[TMP/SMZ]] 5 mg/kg IV q6—12h''''' <SMALL>(TMP component)</SMALL> | | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''No treatment, but if symptomatic, use cold artificial tears''''' |
| |- | | |- |
| |} | | |} |
| |} | | |} |
| |} | | |} |
▸ Click on the following categories to expand treatment regimens.
Conjunctivitis Medical Therapy
▸ Bacterial Conjunctivitis
|
Bacterial Conjunctivitis
|
Preferred Regimen
|
Non-gonococcal
|
▸ Ciprofloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days OR ▸ Gatifloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days OR ▸ Levofloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days OR ▸ Moxifloxacin 1–2 gtts q2h while awake x 1st 2 days, then q4–8h x 7 days
|
Gonococcal
|
Adult dose
|
▸ Ciprofloxacin 1 gm IM/IV as 1 dose
|
Pediatric dose
|
▸ Ciprofloxacin 25-50 mg/kg IV/IM (not to exceed 125 mg) as 1 dose
|
Alternative Regimen (for non-gonococcal only)
|
▸ Polymyxin B + Trimethoprim 1–2 gtts q3–6h x 7–10 days OR ▸ Azithromycin 1%, 1 gtt bid x 2 days, then 1 gtt daily x 5 days
|
Chlamydia Trachomatis
|
Preferred Regimen
|
▸ Azithromycin 1 gm once or twice weekly
|
Alternative Regimen
|
▸ Doxycycline 100 mg bid po x 7 days
|
|
Newborn Conjunctivitis
|
N. gonorrhoeae (after 2-5 days)
|
▸ Ceftriaxone 25-50 mg/kg IV x 1 dose (not to exceed 125 mg)
|
C. trachomatis (after 3-10 days)
|
▸ Erythromycin base or ethyl succinate syrup 12.5 mg/kg q6h x 14 days OR ▸ Azithromycin suspension 20 mg/kg po q24h x 3 days
|
H. simplex (after 2-16 days) †
|
▸ Acyclovir 60 mg/kg/day IV divided into 3 daily doses OR ▸ Trifluridine OR Vidarabine as a topical antiviral therapy
|
† Systemic and CNS disease should be evaluated with PCR of CSF and serum and LFTs in any child with suspected HSV eye infection.
|
|
Viral Conjunctivitis (pink eye)
|
▸ No treatment, but if symptomatic, use cold artificial tears
|
|
|